Organisation paid for research Program year 2021 Source: CMS Open Payments

Almac

Neither a doctor nor a teaching hospital

Research payments

$129,902,170

11 payments

Through program year 2021, Almac is reported as receiving $129,902,170 in research payments, across 11 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$581,994	2
2020	Research	$127,852,581	6
2019	Research	$1,467,595	3

Breakdown

Who paid Research payments · program years 2019–2021

Pfizer Inc. $129,902,170 11 payments

Studies the money was for Research payments · program years 2019–2021

Patinaa Randomized Open Label Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib Antiher2 Therapy Endocrine Therapy VS Antiher2 Therapy Endocrine Therapy After Induction Treatment for Hrher2 Metastatic Breast Cancer $126,859,080 3 payments
A Phase 12 Study of X4p001 in Combination With Axitinib in Patients With Advanced Renal Cell Cancer $2,112,863 6 payments
Sildisafe $518,404 1 payment
Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia $411,824 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.